Moderna gets full US approval for COVID vaccine in children 6 months and older

Moderna's Spikevax COVID-19 vaccine has received full U.S. FDA approval for children aged 6 months through 11 years at increased risk, transitioning from its previous Emergency Use Authorization. This regulatory upgrade comes as Moderna anticipates an updated vaccine for the 2025-26 respiratory virus season, with the company's shares rising 2% in premarket trading following the announcement.

Analysis

Moderna (MRNA.O) has achieved full U.S. Food and Drug Administration (FDA) approval for its Spikevax COVID-19 vaccine for children aged 6 months to 11 years at increased risk, a significant regulatory step up from its previous Emergency Use Authorization. This approval solidifies the vaccine's standing and provides a more permanent commercial pathway within this specific pediatric demographic. The market registered this development favorably, as evidenced by a 2% rise in the company's shares to $33.45 in premarket trading. Looking ahead, Moderna has signaled its pipeline strategy by stating its expectation to introduce an updated vaccine for the 2025-26 respiratory virus season, indicating a focus on maintaining relevance and market share in an evolving post-pandemic environment.

Key Decisions for Investors

• Investors should view the full FDA approval as a positive de-risking event that secures a niche market, but recognize its immediate revenue impact may be limited to the specified high-risk pediatric group.
• The planned updated vaccine for the 2025-26 season is a more critical long-term catalyst, and its development progress and potential market adoption should be monitored closely.
• The modest 2% premarket share increase suggests the market has correctly priced this as an incremental positive rather than a major valuation-changing event, so investors should consider this approval as one part of a broader thesis on Moderna's respiratory vaccine franchise.